Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06193161

Prolonged Exposure for Swedish Immigrants

The goal of this clinical trial is to compare therapist-guided internet delivered prolonged exposure (I-PE) in simple english to a waiting list condition for immigrants in Sweden diagnosed with post-traumatic stress disorder (PTSD).

The main objectives are to establish feasibility and preliminary efficacy of I-PE for immigrants with PTSD in a single-blind, parallel-group superiority Randomized Controlled Trial (N=100) comparing I-PE with a waiting-list condition, starting with a nested pilot (N=30) to ensure feasible and acceptable recruitment and treatment strategies. Study participants will be randomly assigned to either eight weeks of I-PE or a waiting-list for the same amount of time on a 1:1 ratio without restriction. Feasibility and acceptability data will be reported including recruitment rate, sample demographics, data attrition, treatment adherence and a detailed dropout analysis. A preliminary investigation of the within-group effect size will also be conducted. Recruitment is designed to be broadly inclusive with minimal exclusion criteria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

There is an urgent need for dissemination of evidence-based treatments for PTSD beyond the Swedish language criteria and developed in an easy-to-read manner and develop the treatment so that it can be easily made available to a large number of afflicted who are excluded from treatment.The overall aim of the study is to evaluate I-PE for immigrants with PTSD living in Sweden who can read and write easy English. The treatment will be written in easy English and adapted to the target population with regards to specific contextual characteristics.

The study is a single-blind, parallel-group superiority randomized controlled trial with 100 participants that will compare I-PE with a waiting list condition. The primary outcome is the self-rated Posttraumatic Stress Disorder Checklist version 5 (PCL-5) at the 1-month follow up. Secondary outcomes are the blind-rater administered Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), self-rated symptoms of depression quality of life, dropout rate, level of health care utilization, satisfaction with treatment and negative effects. Patients in the control arm will be crossed over to I-PE treatment after completion of the 1 month follow up (primary endpoint). Assessments will be conducted pre-treatment, post-treatment, 1 month (primary endpoint) and 6 months after treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current primary diagnosis of PTSD, according to the diagnostic criteria based on Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5; American Psychiatric Association, 2013)
  • ≥ 18 years
  • Able to read and write in English
  • Immigrant residing in Sweden
  • Able to provide digital informed consent
  • Daily access to a computer or device with internet connection

Exclusion criteria

  • PTSD is not the primary treatment concern
  • Initiation or adjustment of any psychotropic medication within the last 4 weeks prior to commencement of treatment
  • Serious mental health symptoms, such as mania, psychosis, alcohol, or substance use disorders or current suicide risk warranting immediate clinical attention.
  • Ongoing trauma-focused CBT or Eye movement desensitization and reprocessing therapy

Treatment and study plan

Therapist-supported internet delivered prolonged exposure

Behavioral

Therapist-supported internet delivered prolonged exposure for eight weeks.

Primary outcomes

  1. Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)

    Time frame: Baseline, through the treatment period up to eight weeks, and 1-month and 6-month after treatment completion.

    The PCL-5 is a 20-item self-report measure based upon the Diagnostic and Statistical Manual (DSM-5) criteria for PTSD. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.

Secondary outcomes

  1. Change in PTSD symptoms as assessed by the Clinician Administered PTSD Scale (CAPS-5)

    Time frame: Baseline up to 1-month after treatment completion

    The CAPS-5 is structured interview that assesses the Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) criteria for PTSD (Weathers et al., 2013). Each item is rated on a severity scale ranging from 0 (Absent) to 4 (Extreme/incapacitating) and combines information about frequency and intensity for each of the 20 symptoms. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.

  2. Change in depression as assessed by The Patient Health Questionnaire (PHQ-9)

    Time frame: Baseline, immediately after treatment completion, 1-month and 6-month after treatment completion

    The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms. Scores are calculated based on how frequently a person experiences 9 symptoms of depression ranging from "not at all" response is scored as 0; "several days" response is 1; "more than half the days" response is 2; and "nearly every day" response is 3. Higher scores represents more depressive symptoms.

  3. Change in general quality of life assessed by 12-Item Short-Form Health Survey (SF-12)

    Time frame: Baseline, immediately after treatment completion, 1-month and 6-month after treatment completion

    The SF-12 is a health-related quality-of-life questionnaire consisting of twelve questions that measure eight health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP). Scores range from 0 to 100. A higher score means higher health.

  4. Treatment credibility assessed by the Credibility/expectancy scale (CEQ)

    Time frame: Treatment week 3 (three weeks from baseline).

    Measures treatment expectancy and rationale credibility. The CEQ is a 5-item measure of the treatment's credibility and the patients' expectations. The patients assess each domain on a 11-point likert scale (scored 0-10), with a total score ranging between 0-50 where higher score indicates higher credibility and higher expectations.

  5. Change in stigma and barriers related to mental health and competency in mental health assessed by the Stigma-9 Questionnaire (STIG-9),

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

    The STIG-9 consists of nine items assessing cognitive, behavioural and affective aspects of perceived mental health-related stigma. The item responses are summarized in a sum score ranged 0-27 points. Higher scores indicate stronger expectations of negative societal beliefs, feelings, and behaviours towards 'mentally ill' people.

  6. Change in stigma and barriers related to mental health and competency in mental health assessed Barriers to Access to Care Evaluation Scale (BACES)

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

    The Barriers to Access to Care Evaluation (BACE) is a 30-item measure scored from 0 (not at all) to 3 (a lot) with higher scores indicating a greater barrier.

  7. Change in stigma and barriers related to mental health and competency in mental health assessed Mental Health Knowledge Schedule (MHKS)

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

    MHKS is a twelve-item scale comprising domains of relevant evidence-based knowledge in relation to stigma toward mental illness. Items are coded on an ordinal scale (1-5). Items which the respondent strongly agrees with score 5 points; 1 point reflects a response to which the respondent strongly disagrees. The total score is calculated by adding the points obtained for each of the 12 items. Higher total scores correspond to greater knowledge

  8. Change in Treatment inventory of costs associated with psychiatric illness (TIC-P)

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

    Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder. The TIC-P questionnaire measures costs in two dimensions: use of health resources and loss of productivity. Lower cost is better.

  9. Treatment satisfaction measured by the Client Satisfaction Questionnaire (CSQ-8

    Time frame: Immediately after treatment completion

    The CSQ-8 yields a single score measuring a single dimension of overall satisfaction. An "overall score" is calculated by summing the score on each of the eight scale item. Scores range from 8 to 32, with higher values indicating higher satisfaction.

  10. Treatment satisfaction measured by the Internet Evaluation and Utility Questionnaire (IEUQ)

    Time frame: Immediately after treatment completion

    The Internet Evaluation and Utility Questionnaire (IEUQ) is a 13-item measure that examines the participants' experiences of a web-based intervention. Score range from 0-72. Higher values indicating higher satisfaction.

  11. Adverse events related to treatment measured by the Negative effects questionnaire-20.

    Time frame: 1-mont after treatment completion

    Self-rated questionnaire on negative effects. It contains 20 items that are scored on a five point Likert-scale (0-4) and differentiates between negative effects that are attributed to treatment and those possibly caused by other circumstances. The total score of the NEQ ranges from 0 to 80 points, a higher score reflects more negative effects.

Other outcomes

  1. Number of completed treatment modules

    Time frame: Baseline up to treatment completion at 8 weeks

    Data will be gathered on total number of completed modules during the 8 week treatment.

  2. Number of messages sent and received in the digital platform

    Time frame: Baseline up to treatment completion at 8 weeks

    Data will be gathered on total number of messages sent and received back and forth between the participant and the therapist during the 8 week treatment.

  3. Experience with the digital treatment as assessed by qualitative interviews

    Time frame: Immediately after treatment completion

    During the nested study phase a subsample of the participants (N=5-15) will be interviewed at post-treatment regarded treatment comprehension, language adaptions and relevance.

  4. The proportion of participants that conducts the weekly measures and further assessment points

    Time frame: Baseline up to 6-month after treatment completion

    The proportion of participants that conducts the weekly measures and further assessment points

  5. Number of drop-outs from treatment

    Time frame: Completion of the treatment period, up to 8 weeks

    Number of drop-outs from treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Maria Bragesjö, PhD

CONTACT

[email protected]

+46703399387

Olof Molander, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Official study title

Feasibility and Preliminary Efficacy of Internet Delivered Prolonged Exposure Immigrants With PTSD: a Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jan 5, 2024
Registry last updated
Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.